Company Analysis

Ginkgo Bioworks Holdings, Inc. (DNA)

NYSE: DNA · Biological Products, (No Diagnostic Substances) · Boston, MA · filing with the SEC since 2020
Grade4.5
◀ Past 4.1● Present 5.1▶ Future 4.2
1 est.

Who runs Ginkgo Bioworks Holdings, Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Sloan Harry
CEO, Chairman. First filing Feb 2021, latest Jun 15, 2026, 2 filings in all.
Officers reporting now
4
of 7 people with a filing in the last fifteen months
Directors reporting now
3
23 people on the record since 2021
Officerssales are open-market, Oct 21, 2025 to Oct 21, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Coen Steven P.See remarksMay 2023Oct 21, 202610 · $300,000
Kelly Jason RSee remarksSep 2021Oct 21, 20263 · $1.8M
Shetty Reshma P.See remarksSep 2021Oct 21, 20265 · $1.4M
Sloan HarryCEO, ChairmanFeb 2021Jun 15, 2026none
Directorssales are open-market, Oct 21, 2025 to Oct 21, 2026
NameRoleFirst filingLatest filingSales, 12 months
Henry Christian OdirectorSep 2021Sep 16, 20261 · $0.00
Fubini RossdirectorJun 2024Jun 15, 2026none
Kosuri SridirectorNov 2024Jun 15, 2026none
Owners of more than 10% of a classsales are open-market, Oct 21, 2025 to Oct 21, 2026
NameRoleFirst filingLatest filingSales, 12 months
Canton Barry10% ownerSep 2021Oct 21, 20265 · $1.4M
Earlier names on the record26, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton DNA · research, not advice